Immunome (IMNM, $14.06) was a top loser over the last three months, falling -1 to $14.06 per share. A.I.dvisor analyzed 914 stocks in the Biotechnology Industry for the 3-month period ending April 30, 2024, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.